Moreover, since EGPA and GPA with elevated blood eosinophilia share some clinical traits, diagnostic confusion may lead to inappropriate therapy, e.g., some “eosinophilic” GPA patients may benefit from anti-IL-5 strategy, usually not recommended in AVV other than EGPA. This evidence concerns the gene IL5 and Increased total eosinophil count.